Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

13.62
-0.1100-0.80%
Pre-market: 13.47-0.1500-1.10%08:05 EDT
Volume:5.43M
Turnover:73.87M
Market Cap:10.87B
PE:-12.19
High:13.73
Open:13.51
Low:13.44
Close:13.73
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.87
T/O Rate:3.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:17.25
PE(LYR):-9.43

Loading ...

Miliband refused to meet motor trade body to discuss zero emissions mandate

cityam
·
Jul 30

Vehicle production drops in first half of year

cityam
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)

TIPRANKS
·
Jul 29

Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)

TIPRANKS
·
Jul 27

Summit Therapeutics (SMMT) Updates Ivonescimab Progress, Is The 52% Undervalued View Convincing?

Simply Wall St.
·
Jul 27

Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations

TIPRANKS
·
Jul 25

Summit Therapeutics Flags Going Concern Risk Over Cash Needs

Benzinga Earnings
·
Jul 24

U.S. Stocks on the Move-booz Allen Hamilton, Sensient, Amkor

Reuters
·
Jul 24

U.S. Stocks on the Move-tenet Healthcare, Intel, Verizon

Reuters
·
Jul 24

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Summit Therapeutics (SMMT) and Progyny (PGNY)

TIPRANKS
·
Jul 24

Summit Therapeutics Falls After Share Sale Plans, Q2 Report

Reuters
·
Jul 24

Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Jul 24

Stock Track | Summit Therapeutics PLC Plunges 5.54% Intraday on Widening Non-GAAP Loss and $380 Million Stock Offering Plan

Stock Track
·
Jul 24

Summit Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 24

Summit Therapeutics Launches At-the-market Equity Program for up to $380 Million

Reuters
·
Jul 24

Stock Track | Summit Therapeutics Plunges 6% After-Hours as Non-GAAP Loss Widens on Surging Ivonescimab Development Costs

Stock Track
·
Jul 24

Summit Therapeutics says will need to raise additional capital

TIPRANKS
·
Jul 24

Summit Therapeutics - to Offer and Sell Common Stock up to $380 Mln Aggregate Through Sales Agent - SEC Filing

THOMSON REUTERS
·
Jul 24

Summit Therapeutics Q2 FY26 Net Loss Narrows to $215.7 Million

Reuters
·
Jul 24

Summit Therapeutics Q2 Net Income USD -215.7 Million

Reuters
·
Jul 24